- Home
- IFBD vs KPRX Comparison
IFBD vs KPRX Comparison
Compare IFBD & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFBD
- KPRX
- Stock Information
- Founded
- IFBD 2001
- KPRX 1998
- Country
- IFBD China
- KPRX United States
- Employees
- IFBD N/A
- KPRX N/A
- Industry
- IFBD Computer Software: Prepackaged Software
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IFBD Technology
- KPRX Health Care
- Exchange
- IFBD Nasdaq
- KPRX Nasdaq
- Market Cap
- IFBD 8.4M
- KPRX 8.6M
- IPO Year
- IFBD 2021
- KPRX N/A
- Fundamental
- Price
- IFBD $1.01
- KPRX $2.60
- Analyst Decision
- IFBD
- KPRX Strong Buy
- Analyst Count
- IFBD 0
- KPRX 1
- Target Price
- IFBD N/A
- KPRX $10.00
- AVG Volume (30 Days)
- IFBD 10.3K
- KPRX 67.1K
- Earning Date
- IFBD 05-01-2023
- KPRX 08-08-2025
- Dividend Yield
- IFBD N/A
- KPRX N/A
- EPS Growth
- IFBD N/A
- KPRX N/A
- EPS
- IFBD N/A
- KPRX N/A
- Revenue
- IFBD $1,437,848.00
- KPRX $20,000.00
- Revenue This Year
- IFBD N/A
- KPRX N/A
- Revenue Next Year
- IFBD N/A
- KPRX N/A
- P/E Ratio
- IFBD N/A
- KPRX N/A
- Revenue Growth
- IFBD 413.52
- KPRX N/A
- 52 Week Low
- IFBD $0.89
- KPRX $2.51
- 52 Week High
- IFBD $3.32
- KPRX $4.80
- Technical
- Relative Strength Index (RSI)
- IFBD 42.50
- KPRX 32.25
- Support Level
- IFBD $1.01
- KPRX $2.96
- Resistance Level
- IFBD $1.08
- KPRX $3.29
- Average True Range (ATR)
- IFBD 0.04
- KPRX 0.14
- MACD
- IFBD -0.00
- KPRX -0.05
- Stochastic Oscillator
- IFBD 14.73
- KPRX 1.43
About IFBD Infobird Co. Ltd
Infobird Co Ltd is engaged in developing and providing customer engagement cloud-based services. It software-as-a-service provider of AI-powered, or artificial intelligence-enabled, customer engagement solutions in China. It provides holistic software solutions to help corporate clients proactively deliver and manage end-to-end customer engagement activities at all stages of the sales process, including pre-sales and sales activities, and post-sales customer support. It also offers AI-powered cloud-based sales force management software, including intelligent quality inspection and intelligent training software to help clients monitor, benchmark, and improve the performance of agents.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.